A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma - GHG-GCD

Tsurumi Hisashi0 个研究点目标入组 20 人开始时间: 2023年10月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients have pathologically confirmed refractory or relapsed non-Hodgkin lymphoma.
•2) Patients had received prior treatment of rituximab in combination with CHOP or THP-COP.
•3) Patients aged >= 18 years.
•4) ECOG performance status of 0-2
•5) Patients have measurable lesion.
•6) Patients without interstitial pneumonia or pulmonary fibrosis evidenced by chest X-ray and/or chest CT.
•7) Patients have a life expectancy > 12 weeks.
•8) Written informed consent.
•9) Patients meet all following standard.
•- Absolute neutrophil count >= 1,000/mm3
•- Hemoglobin >= 8.0 g/dL
•- Platelet count >= 75,000/mm3
•- AST and ALT < 2.5 times facility criteria.
•- Total bilirubin < 2.5 times facility criteria.

•1) Patients have CNS invasion.
•2) HIV antibody positive.
•3) Patients have interstitial pneumonia or pulmonary fibrosis evidenced by chest X-ray and/or chest CT.
•4) Patients undergoing chest radiotherapy.
•5) Patients have major heart/lung disorders, or uncontrolled diabetes mellitus.
•6) Patients are pregnant or lactating women. Patients cannot or will not use birth control during the treatment.
•7) Patients have active other malignant diseases.
•8) Patients have severe allergic symptoms.
•9) Patients have chemotherapy resistant lymphoma.
•10) Inadequate for clinical trial entry by the attending physicians.

发起方

Tsurumi Hisashi